Treatment with a sphingosine analog after the inception of house dust mite-induced airway inflammation alleviates key features of experimental asthma

Respiratory Research

David Marsolais¹  Élyse Bissonnette¹  Ynuk Bossé¹  Anthony S Don³  Marie-Renée Blanchet¹  Nicolas Flamand¹  Émilie Bernatchez⁴  Anick Langlois⁴  Laetitia JA Lai⁴  Claudine Tremblay²  Anne-Marie Lemay⁴  David Gendron⁴ 

[1] Département de Médecine, Faculté de Médecine, Université Laval, Québec, QC, Canada;Laboratoires Charles River, Services Précliniques, Montréal, Canada;Prince of Wales Clinical School, Faculty of Medicine, University of New South Wales, Sydney 2052, NSW, Australia;Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec (CRIUCPQ), Québec, QC, Canada

关键词: Sphingosine;    AAL-S;    AAL-R;    S1P;    Asthma;    CD4+ T cells;    Dendritic cells;    Apoptosis;    Dermatophagoides pteronyssinus;    Gilenya;    Fingolimod;    FTY720;   

Others  :  1135872
DOI  :  10.1186/s12931-015-0180-z

 received in 2014-08-06, accepted in 2015-01-21,  发布年份 2015

【 摘 要 】

Background

In vivo phosphorylation of sphingosine analogs with their ensuing binding and activation of their cell-surface sphingosine-1-phosphate receptors is regarded as the main immunomodulatory mechanism of this new class of drugs. Prophylactic treatment with sphingosine analogs interferes with experimental asthma by impeding the migration of dendritic cells to draining lymph nodes. However, whether these drugs can also alleviate allergic airway inflammation after its onset remains to be determined. Herein, we investigated to which extent and by which mechanisms the sphingosine analog AAL-R interferes with key features of asthma in a murine model during ongoing allergic inflammation induced by Dermatophagoides pteronyssinus.

Methods

BALB/c mice were exposed to either D. pteronyssinus or saline, intranasally, once-daily for 10 consecutive days. Mice were treated intratracheally with either AAL-R, its pre-phosphorylated form AFD-R, or the vehicle before every allergen challenge over the last four days, i.e. after the onset of allergic airway inflammation. On day 11, airway responsiveness to methacholine was measured; inflammatory cells and cytokines were quantified in the airways; and the numbers and/or viability of T cells, B cells and dendritic cells were assessed in the lungs and draining lymph nodes.

Results

AAL-R decreased airway hyperresponsiveness induced by D. pteronyssinus by nearly 70%. This was associated with a strong reduction of IL-5 and IL-13 levels in the airways and with a decreased eosinophilic response. Notably, the lung CD4⁺ T cells were almost entirely eliminated by AAL-R, which concurred with enhanced apoptosis/necrosis in that cell population. This inhibition occurred in the absence of dendritic cell number modulation in draining lymph nodes. On the other hand, the pre-phosphorylated form AFD-R, which preferentially acts on cell-surface sphingosine-1-phosphate receptors, was relatively impotent at enhancing cell death, which led to a less efficient control of T cell and eosinophil responses in the lungs.

Conclusion

Airway delivery of the non-phosphorylated sphingosine analog, but not its pre-phosphorylated counterpart, is highly efficient at controlling the local T cell response after the onset of allergic airway inflammation. The mechanism appears to involve local induction of lymphocyte apoptosis/necrosis, while mildly affecting dendritic cell and T cell accumulation in draining lymph nodes.

【 授权许可】

   
2015 Gendron et al.; licensee BioMed Central.

【 图 表 】

Figure 4.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Facts on asthma. [http://www.who.int/mediacentre/factsheets/fs307/en/index.html]
• [2]Pawankar R, Canonica GW, Holgate ST, Lockey RF: Allergic diseases and asthma: a major global health concern. Curr Opin Allergy Clin Immunol 2012, 12:39-41.
• [3]Cazzoletti L, Marcon A, Janson C, Corsico A, Jarvis D, Pin I, et al.: Asthma control in Europe: a real-world evaluation based on an international population-based study. J Allergy Clin Immunol 2007, 120:1360-7.
• [4]Barnes PJ, Adcock IM: Glucocorticoid resistance in inflammatory diseases. Lancet 2009, 373:1905-17.
• [5]Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, et al.: Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006, 355:1124-40.
• [6]Collison A, Hatchwell L, Verrills N, Wark PA, de Siqueira AP, Tooze M, et al.: The E3 ubiquitin ligase midline 1 promotes allergen and rhinovirus-induced asthma by inhibiting protein phosphatase 2A activity. Nat Med 2013, 19:232-7.
• [7]Jary E, Bee T, Walker SR, Chung SK, Seo KC, Morris JC, et al.: Elimination of a hydroxyl group in FTY720 dramatically improves the phosphorylation rate. Mol Pharmacol 2010, 78:685-92.
• [8]Marsolais D, Rosen H: Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules. Nat Rev Drug Discov 2009, 8:297-307.
• [9]Marsolais D, Hahm B, Walsh KB, Edelmann KH, McGavern D, Hatta Y, et al.: A critical role for the sphingosine analog AAL-R in dampening the cytokine response during influenza virus infection. Proc Natl Acad Sci U S A 2009, 106:1560-5.
• [10]Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, et al.: Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002, 296:346-9.
• [11]Don AS, Martinez-Lamenca C, Webb WR, Proia RL, Roberts E, Rosen H: Essential requirement for sphingosine kinase 2 in a sphingolipid apoptosis pathway activated by FTY720 analogues. J Biol Chem 2007, 282:15833-42.
• [12]Payne SG, Oskeritzian CA, Griffiths R, Subramanian P, Barbour SE, Chalfant CE, et al.: The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors. Blood 2007, 109:1077-85.
• [13]Marsolais D, Yagi S, Kago T, Leaf N, Rosen H: Modulation of chemokines and allergic airway inflammation by selective local sphingosine-1-phosphate receptor 1 agonism in lungs. Mol Pharmacol 2011, 79:61-8.
• [14]Idzko M, Hammad H, van Nimwegen M, Kool M, Muller T, Soullie T, et al.: Local application of FTY720 to the lung abrogates experimental asthma by altering dendritic cell function. J Clin Invest 2006, 116:2935-44.
• [15]Gandhi VD, Davidson C, Asaduzzaman M, Nahirney D, Vliagoftis H: House dust mite interactions with airway epithelium: role in allergic airway inflammation. Curr Allergy Asthma Rep 2013, 13:262-70.
• [16]Cates EC, Fattouh R, Johnson JR, Llop-Guevara A, Jordana M: Modeling responses to respiratory house dust mite exposure. Contrib Microbiol 2007, 14:42-67.
• [17]Blanchet MR, Maltby S, Haddon DJ, Merkens H, Zbytnuik L, McNagny KM: CD34 facilitates the development of allergic asthma. Blood 2007, 110:2005-12.
• [18]Blais Lecours P, Duchaine C, Taillefer M, Tremblay C, Veillette M, Cormier Y, et al.: Immunogenic properties of archaeal species found in bioaerosols. PLoS One 2011, 6:e23326.
• [19]Kiuchi M, Adachi K, Kohara T, Minoguchi M, Hanano T, Aoki Y, et al.: Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1,3-diols and 2-aminoethanols. J Med Chem 2000, 43:2946-61.
• [20]Kiuchi M, Adachi K, Kohara T, Teshima K, Masubuchi Y, Mishina T, et al.: Synthesis and biological evaluation of 2,2-disubstituted 2-aminoethanols: analogues of FTY720. Bioorg Med Chem Lett 1998, 8:101-6.
• [21]Marsolais D, Hahm B, Edelmann KH, Walsh KB, Guerrero M, Hatta Y, et al.: Local not systemic modulation of dendritic cell S1P receptors in lung blunts virus-specific immune responses to influenza. Mol Pharmacol 2008, 74:896-903.
• [22]Mann PC, Vahle J, Keenan CM, Baker JF, Bradley AE, Goodman DG, et al.: International harmonization of toxicologic pathology nomenclature: an overview and review of basic principles. Toxicol Pathol 2012, 40:7S-13.
• [23]Shackelford C, Long G, Wolf J, Okerberg C, Herbert R: Qualitative and quantitative analysis of nonneoplastic lesions in toxicology studies. Toxicol Pathol 2002, 30:93-6.
• [24]Laflamme C, Israel-Assayag E, Cormier Y: Apoptosis of bronchoalveolar lavage lymphocytes in hypersensitivity pneumonitis. Eur Respir J 2003, 21:225-31.
• [25]Price MM, Oskeritzian CA, Falanga YT, Harikumar KB, Allegood JC, Alvarez SE, et al.: A specific sphingosine kinase 1 inhibitor attenuates airway hyperresponsiveness and inflammation in a mast cell-dependent murine model of allergic asthma. J Allergy Clin Immunol 2013, 131:501-11. e501
• [26]Holgate ST: The sentinel role of the airway epithelium in asthma pathogenesis. Immunol Rev 2011, 242:205-19.
• [27]Holmes AM, Solari R, Holgate ST: Animal models of asthma: value, limitations and opportunities for alternative approaches. Drug Discov Today 2011, 16:659-70.
• [28]Kleinjan A, van Nimwegen M, Leman K, Hoogsteden HC, Lambrecht BN: Topical treatment targeting sphingosine-1-phosphate and sphingosine lyase abrogates experimental allergic rhinitis in a murine model. Allergy 2013, 68:204-12.
• [29]Bosse Y, Pare P: The contractile properties of airway smooth muscle: How their defects can be linked to asthmatic airway hyperresponsiveness? Current Respiratory Medicine Reviews 2013, 9:42-68.
• [30]Matusovsky OS, Nakada EM, Kachmar L, Fixman ED, Lauzon AM: CD4+ T cells enhance the unloaded shortening velocity of airway smooth muscle by altering the contractile protein expression. J Physiol 2014, 592:2999-3012.
• [31]Ramos-Barbon D, Presley JF, Hamid QA, Fixman ED, Martin JG: Antigen-specific CD4+ T cells drive airway smooth muscle remodeling in experimental asthma. J Clin Invest 2005, 115:1580-9.
• [32]Matheu MP, Teijaro JR, Walsh KB, Greenberg ML, Marsolais D, Parker I, et al.: Three phases of CD8 T cell response in the lung following H1N1 influenza infection and sphingosine 1 phosphate agonist therapy. PLoS One 2013, 8:e58033.
• [33]Gollmann G, Neuwirt H, Tripp CH, Mueller H, Konwalinka G, Heufler C, et al.: Sphingosine-1-phosphate receptor type-1 agonism impairs blood dendritic cell chemotaxis and skin dendritic cell migration to lymph nodes under inflammatory conditions. Int Immunol 2008, 20:911-23.
• [34]Hutchison S, Choo-Kang BS, Gibson VB, Bundick RV, Leishman AJ, Brewer JM, et al.: An investigation of the impact of the location and timing of antigen-specific T cell division on airways inflammation. Clin Exp Immunol 2009, 155:107-16.
• [35]Karmouty-Quintana H, Siddiqui S, Hassan M, Tsuchiya K, Risse PA, Xicota-Vila L, et al.: Treatment with a sphingosine-1-phosphate analog inhibits airway remodeling following repeated allergen exposure. Am J Physiol Lung Cell Mol Physiol 2012, 302:L736-45.
• [36]Hashimoto D, Asakura S, Matsuoka K, Sakoda Y, Koyama M, Aoyama K, et al.: FTY720 enhances the activation-induced apoptosis of donor T cells and modulates graft-versus-host disease. Eur J Immunol 2007, 37:271-81.
• [37]Zeng X, Wang T, Zhu C, Xing X, Ye Y, Lai X, et al.: Topographical and biological evidence revealed FTY720-mediated anergy-polarization of mouse bone marrow-derived dendritic cells in vitro. PLoS One 2012, 7:e34830.
• [38]Nagahara Y, Enosawa S, Ikekita M, Suzuki S, Shinomiya T: Evidence that FTY720 induces T cell apoptosis in vivo. Immunopharmacology 2000, 48:75-85.
• [39]Spinozzi F, Agea E, Bistoni O, Forenza N, Monaco A, Bassotti G, et al.: Increased allergen-specific, steroid-sensitive gamma delta T cells in bronchoalveolar lavage fluid from patients with asthma. Ann Intern Med 1996, 124:223-7.
• [40]Dorscheid DR, Wojcik KR, Sun S, Marroquin B, White SR: Apoptosis of airway epithelial cells induced by corticosteroids. Am J Respir Crit Care Med 2001, 164:1939-47.
• [41]Hofmann M, Brinkmann V, Zerwes HG: FTY720 preferentially depletes naive T cells from peripheral and lymphoid organs. Int Immunopharmacol 2006, 6:1902-10.